Response

Affiliations

¹ Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Electronic address: anthony.durmowicz@fda.hhs.gov.
² Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
³ Office of New Drugs and the Office of Drug Evaluation 2, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Comment

Anthony G Durmowicz et al. Chest. 2013 Oct.

. 2013 Oct;144(4):1418-1419.

doi: 10.1378/chest.13-1517.

¹ Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Electronic address: anthony.durmowicz@fda.hhs.gov.
² Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
³ Office of New Drugs and the Office of Drug Evaluation 2, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

No abstract available

Comment on

Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Durmowicz AG, et al. Chest. 2013 Jan;143(1):14-18. doi: 10.1378/chest.12-1430. Chest. 2013. PMID: 23276841
Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
Heltshe SL, Mayer-Hamblett N, Rowe SM. Heltshe SL, et al. Chest. 2013 Oct;144(4):1418. doi: 10.1378/chest.13-1320. Chest. 2013. PMID: 24081360 Free PMC article. No abstract available.